Latest news with #Piramal
India.com
4 days ago
- Business
- India.com
Meet man who runs family business worth Rs 837520000000000, owns fleet of luxury cars, shares close relationship with Mukesh Ambani, Isha Ambani, he is…
Meet man who runs family business worth Rs 837520000000000, owns fleet of luxury cars, shares close relationship with Mukesh Ambani, Isha Ambani, he is… Anand Piramal, son-in-law of billionaire Mukesh Ambani and Nita Ambani, is the Executive Director at the Piramal Group. He is an important member of the Piramal group responsible for leading its financial services and real estate businesses. Valued at Rs 83,752 crore, the Piramal Group spans sectors such as real estate, healthcare, financial services, and pharmaceuticals. Under his leadership, the retail lending business has become one of the fastest-growing large retail NBFCs in the country, serving over 4 million customers across the country. Speaking of his educational qualifications, Anand Piramal, husband of Isha Ambani, pursued his master's degree in business administration from Harvard Business School. Not only this, but Anand earned a bachelor's degree in economics from the University of Pennsylvania. In 2024, he was recognised as one of India's '40 under 40' young leaders by The Economic Times and Fortune India. Meet man who runs family business worth Rs 837520000000000, owns fleet of luxury cars, shares close relationship with Mukesh Ambani, Isha Ambani, he is… According to the official website, Piramal Group is a global business conglomerate with diverse interests in pharmaceuticals, financial services, and real estate, with offices in 30 countries and its products sold in more than 100 markets. Although Anand Piramal's net worth isn't publicly available online, his father Ajay Piramal's net worth is said to be reportedly at $2.8 billion (around Rs 25,000 crore). According to Forbes, Ajay Piramal's net worth as per real time is estimated to be $ 3.4 B. He is ranked 1,172nd on Forbes' World's Billionaires List: The Richest in 2025. As a wedding gift, Anand and Isha were presented with a luxurious 50,000 sq ft residence named 'Gulita' in Mumbai's Worli area by their parents. Worth $100 million in 2022, the house has three basements, several dining rooms, an outdoor pool, a garden, a grand hall, and a diamond-themed bungalow. Anand also possesses a massive collection of luxury cars, including a Mercedes Maybach 3600 (Rs 10 crore), Aston Martin Rapide (Rs 3.29 crore), Lamborghini Gallardo (Rs 3 crore), Mercedes-Benz S350D (Rs 1.4 crore), and Range Rover Sports (Rs 1 crore). Isha and Anand tied the knot in December 2018 and are considered one of India's most powerful business couples. Anand's success and luxurious lifestyle are the result of his hard work and sharp business decisions
Time of India
16-05-2025
- Business
- Time of India
Piramal Pharma to stay away from prescription business in India: Nandini Piramal
Mumbai: Piramal Pharma has no plans to enter domestic prescription formulations business for now, chairperson Nandini Piramal told ET, putting to rest speculations that the company is evaluating acquisitions in this space. The company, however, may consider acquiring over-the-counter (OTC) portfolios or individual brands and products for its India-focused consumer healthcare business , which crossed the strategic revenue milestone of ₹1,000 crore in FY25. It may also evaluate targets in its global complex hospital generics business. Piramal explained that rivals that already have a prescription business would be willing to pay more for an acquisition target as they would get immediate synergies. "So, the amount that they can afford to pay versus wouldn't have that," she said. Play Video Pause Skip Backward Skip Forward Unmute Current Time 0:00 / Duration 0:00 Loaded : 0% 0:00 Stream Type LIVE Seek to live, currently behind live LIVE Remaining Time - 0:00 1x Playback Rate Chapters Chapters Descriptions descriptions off , selected Captions captions settings , opens captions settings dialog captions off , selected Audio Track default , selected Picture-in-Picture Fullscreen This is a modal window. Beginning of dialog window. Escape will cancel and close the window. Text Color White Black Red Green Blue Yellow Magenta Cyan Opacity Opaque Semi-Transparent Text Background Color Black White Red Green Blue Yellow Magenta Cyan Opacity Opaque Semi-Transparent Transparent Caption Area Background Color Black White Red Green Blue Yellow Magenta Cyan Opacity Transparent Semi-Transparent Opaque Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Drop shadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps Reset restore all settings to the default values Done Close Modal Dialog End of dialog window. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Elegant New Scooters For Seniors In 2024: The Prices May Surprise You Mobility Scooter | Search Ads Learn More Undo Piramal Pharma sold its domestic formulation business to Abbott for $3.8 billion in 2010. On its future growth strategy, the chairperson said the company will continue to focus on organic brownfield expansion in the drug development and manufacturing service business, or Contract Development and Manufacturing Organisation ( CDMO ). Live Events The company is looking at capex of $100-125 million, she said. Talking about the current global headwinds, Piramal said near-term macroeconomic uncertainty and uneven improvement in biotech funding is leading to customers taking more time to decide and place orders, thus leading to lower capacity utilisation in the overseas CDMO sites. However, the company's India sites are running at a healthy utilisation level, she said. "In many of our overseas sites, we have recently made investments and hence their utilisation will gradually pick up as we fill them with new orders," she added. About 69% of Piramal Pharma's revenue comes from regulated markets like the US, UK, Europe and Japan. On overall future product pipeline, Piramal said there are 31 products in phase 3 trial, 30 in phase 2, and 177 in phase 1. The company posted 8% year-on-year growth in revenue from operations for the fourth quarter of FY25 ended March and 12% growth for the full fiscal, driven primarily by CDMO business, especially from on-patent commercial manufacturing. Its net debt-to-Ebitda ratio improved to 2.7x in FY25 versus 5.6x in FY23.
Mint
15-05-2025
- Business
- Mint
Piramal Pharma CDMO growth hit by US policy jitters; recovery seen in FY27
Piramal Pharma anticipates muted, single-digit growth for its contract development and manufacturing organization (CDMO) business in FY26, hurt by near-term uncertainties as clients defer decisions amid concerns over US pricing and tariff policies, a top company official said. However, the Mumbai-based firm expects a quick recovery in FY27, and is on track to achieve its target of becoming a $2-billion company with 25% Ebitda (earnings before interest, taxes, depreciation, and amortization) margins by FY30, chairperson Nandini Piramal told Mint. 'There's been an increase in uncertainty and volatility…wher you've got pricing [cuts], whether you've got tariffs, or biotech funding which has been kind of uneven,' Piramal said. 'A lot of customers are pausing on decision-making,' She said, adding that the company has seen an increase in requests for proposals (RFPs) from potential clients. 'They're trying to scenario-play all the options.' A CDMO is a company that provides comprehensive services, from drug development to clinical trials and drug manufacturing to other pharmaceutical and biotech firms on a contract basis. 'In FY27, we should see a significant and a strong recovery,' she added. Earlier this week, Trump signed an executive order to bring down the costs of prescription drugs in the US to match the cheapest global prices. Additionally, he has indicated imposing import tariffs on pharmaceutical products with the view of bringing manufacturing back to US. However, a lot of uncertainty persists over the implementation and details of these orders. Piramal Pharma expects steady growth for its consumer healthcare business and complex hospital generics in the coming year, she said, adding that the company is well-poised to service demand in the CDMO business. 'Once the uncertainty dies down, we have the capacity and the capabilities and one of the best networks in the US, the UK, and India, depending on where our customers want to manufacture their products,' Piramal said. The CDMO business contributed 59% to Piramal Pharma's overall revenues in FY25. Earlier this week, the firm announced a $90 million investment to expand its manufacturing capabilities at two key US facilities - Lexington in Kentucky and Riverview in Michigan. Piramal said that there has been a rise in demand for onshoring post-covid, 'especially for on-patent pharmaceuticals and some of the more complex drugs…to be closer to the customer'. The expansion of the Lexington facility is expected to be completed by calendar year 2027, while the Riverview facility expansion will be completed this calendar year. The company saw significant recovery in FY24 and FY25, with a 14% compounded annual growth rate (CAGR), over 500 bps of Ebitda margin enhancement, and significant improvement in net profits, the company said in an investor presentation. It also brought down its net debt/Ebitda level from 5.6x in FY23 to 2.7x in FY25. 'Over the last couple of years, we've very good growth in our patent innovation-related work in the CDMO business, and that has led to giving us operating leverage and an improvement in Ebitda,' Piramal said. The company expects strong market growth for its India-focused consumer healthcare business, which crossed the ₹ 1,000 crore revenue milestone this year. 'We're also looking at focusing on expanding our distribution from being just a canvas focus in e-commerce, to now broadening to modern trade, quick commerce, stand-alone supermarkets,' Piramal said. For its complex hospital generics business, the company intends to leverage its recently commercialised Sevoflurane facility to expand into the rest of world (RoW) markets. Piramal Pharma currently holds 44% market share for Sevoflurane, an inhaled anaesthetic, in the US. The company expects to expand into other markets inFY26. Sevoflurane has a $400-million global market, Piramal said. The company posted its financial results for Q4FY25 and FY25 on Wednesday. Its revenue grew 8% year-on-year to ₹ 2,754 crore in Q4FY25, and 12% in FY25 to ₹ 9,151 crore, driven primarily by the CDMO business especially from on-patent commercial manufacturing. Ebitda rose 8% year-on-year to ₹ 603 crore in Q4FY25 and 15% YoY to ₹ 1,580 crore in the fiscal year ended 31 March, driven by operating leverage, cost optimization, and operational excellence initiatives, the company said.
Cision Canada
12-05-2025
- Business
- Cision Canada
Piramal Pharma Ltd. Continues to Invest In USA; $90M in Expansions of Two US Sites
Addition of commercial-scale sterile injectables capabilities in Lexington, KY Addition of development and commercial-scale capabilities in payload-linkers for bioconjugates in Riverview, MI This is incremental to Piramal's prior investments of $570 M in the US MUMBAI, India, May 12, 2025 /CNW/ -- Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, in conjunction with the 2025 SelectUSA Investment Summit, commits to a $90M investment plan towards expanding two of the Company's US facilities. These expansions are in response to ongoing demand from US customers, in support of the trend towards US onshoring of drug supply, and in line with Piramal Pharma's overall belief in the value and benefits of US-based innovation. In both cases, Piramal Pharma is making brownfield expansions to existing sites, financed by bank loans and internal accruals, which is the fastest, lowest risk, and most economical way to add new capacities to the US market. Piramal Pharma's Lexington, Kentucky, facility specializes in sterile compounding, liquid filling, and lyophilization for sterile injectable drug products. The site's expansion—which includes 24,000 square feet of manufacturing space and a new laboratory—adds commercial-scale manufacturing that will enable the efficient scale-up of clients' injectable drug products. Key additions include a new filling line, two commercial-size lyophilizers, a special capping machine, and an external vial washer. The facility is expected to be completed and online by late 2027. Piramal Pharma's Riverview, Michigan site, has earned a reputation as an industry leader in the development and manufacturing of active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs) over the past 50+ years. Here, the company is adding a commercial-scale suite specifically for the development and manufacturing of payload-linkers. These high potency APIs are used in the development of antibody-drug conjugates (ADCs) and other bioconjugate drugs. The new payload-linker suite is expected to be operational before the end of 2025. These site expansions are expected to generate greater opportunities for integrated ADC projects. Working synergistically, they will play a vital role in Piramal Pharma's integrated ADC development and manufacturing program, branded ADCelerate™. With development and commercial-scale capabilities in mABs, payload-linkers, conjugations, and fill/finish, ADCelerate speeds timelines, enabling project initiation to GMP drug product in just 12 months with uncompromised quality. This capability strengthens Piramal Pharma's position as an efficient and reliable global partner for biologic manufacturing. "Since its inception, Piramal Pharma Ltd has invested $570 million in its US drug development and manufacturing capabilities," said Peter DeYoung, Chief Executive Officer, Global Pharma. "The US is our largest market, where we currently employ approximately 750 people. Expanding the capacities and offerings in these two plants in the US, along with the prior major investments made in our Sellersville PA drug product facility, and our inhalation anesthesia drug substance and drug product facility in Bethlehem PA, will support our customers who value our offerings in an onshore setting." As a patient centric organization, Piramal Pharma is committed to supporting our customers in their quest to reduce the burden of disease on patients. These expansions bring commercial-scale support to two important and fast-growing segments of drug development. Payload-linkers are fundamental to the process of building bioconjugates, which are the platform for numerous oncology drugs. Sterile fill/finish represents the final stage of manufacturing for injectable drugs. Collectively, these expansions support our integrated drug development and manufacturing services and will ultimately get more treatments into patients on faster timelines. About Piramal Pharma Limited: Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments. * Includes one facility via PPL's minority investment in Yapan Bio.
Yahoo
12-05-2025
- Business
- Yahoo
Piramal Pharma Ltd. Continues to Invest In USA; $90M in Expansions of Two US Sites
Addition of commercial-scale sterile injectables capabilities in Lexington, KY Addition of development and commercial-scale capabilities in payload-linkers for bioconjugates in Riverview, MI This is incremental to Piramal's prior investments of $570 M in the US MUMBAI, India, May 12, 2025 /CNW/ -- Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, in conjunction with the 2025 SelectUSA Investment Summit, commits to a $90M investment plan towards expanding two of the Company's US facilities. These expansions are in response to ongoing demand from US customers, in support of the trend towards US onshoring of drug supply, and in line with Piramal Pharma's overall belief in the value and benefits of US-based innovation. In both cases, Piramal Pharma is making brownfield expansions to existing sites, financed by bank loans and internal accruals, which is the fastest, lowest risk, and most economical way to add new capacities to the US market. Piramal Pharma's Lexington, Kentucky, facility specializes in sterile compounding, liquid filling, and lyophilization for sterile injectable drug products. The site's expansion—which includes 24,000 square feet of manufacturing space and a new laboratory—adds commercial-scale manufacturing that will enable the efficient scale-up of clients' injectable drug products. Key additions include a new filling line, two commercial-size lyophilizers, a special capping machine, and an external vial washer. The facility is expected to be completed and online by late 2027. Piramal Pharma's Riverview, Michigan site, has earned a reputation as an industry leader in the development and manufacturing of active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs) over the past 50+ years. Here, the company is adding a commercial-scale suite specifically for the development and manufacturing of payload-linkers. These high potency APIs are used in the development of antibody-drug conjugates (ADCs) and other bioconjugate drugs. The new payload-linker suite is expected to be operational before the end of 2025. These site expansions are expected to generate greater opportunities for integrated ADC projects. Working synergistically, they will play a vital role in Piramal Pharma's integrated ADC development and manufacturing program, branded ADCelerate™. With development and commercial-scale capabilities in mABs, payload-linkers, conjugations, and fill/finish, ADCelerate speeds timelines, enabling project initiation to GMP drug product in just 12 months with uncompromised quality. This capability strengthens Piramal Pharma's position as an efficient and reliable global partner for biologic manufacturing. "Since its inception, Piramal Pharma Ltd has invested $570 million in its US drug development and manufacturing capabilities," said Peter DeYoung, Chief Executive Officer, Global Pharma. "The US is our largest market, where we currently employ approximately 750 people. Expanding the capacities and offerings in these two plants in the US, along with the prior major investments made in our Sellersville PA drug product facility, and our inhalation anesthesia drug substance and drug product facility in Bethlehem PA, will support our customers who value our offerings in an onshore setting." As a patient centric organization, Piramal Pharma is committed to supporting our customers in their quest to reduce the burden of disease on patients. These expansions bring commercial-scale support to two important and fast-growing segments of drug development. Payload-linkers are fundamental to the process of building bioconjugates, which are the platform for numerous oncology drugs. Sterile fill/finish represents the final stage of manufacturing for injectable drugs. Collectively, these expansions support our integrated drug development and manufacturing services and will ultimately get more treatments into patients on faster timelines. About Piramal Pharma Limited: Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments. For more information, visit: Piramal Pharma | LinkedIn * Includes one facility via PPL's minority investment in Yapan Bio. Photo: View original content to download multimedia: SOURCE Piramal Pharma Ltd View original content to download multimedia:
